Abstract
People with Down syndrome develop Alzheimer's disease with an early age of onset. Plasma amyloid beta (Abeta) levels were measured in individuals with Down syndrome who were over the age of 40. No associations between age and Abeta1-40 and Abeta1-42 concentrations were found and nor were Abeta1-40 and Abeta1-42 levels found to vary between those with Alzheimer's-type dementia and those without dementia. The APOE genotype was not found to have an impact upon Abeta1-40 or Abeta1-42 concentrations. These data suggest that other factors play important roles in determining the onset and progression of dementia in the Down syndrome population.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Age Factors
-
Aged
-
Aging / metabolism*
-
Aging / pathology
-
Alzheimer Disease / blood*
-
Alzheimer Disease / genetics
-
Alzheimer Disease / physiopathology
-
Amyloid beta-Peptides / analysis
-
Amyloid beta-Peptides / blood*
-
Apolipoproteins E / genetics
-
Biomarkers / analysis
-
Biomarkers / blood
-
Comorbidity
-
Down Syndrome / blood*
-
Down Syndrome / genetics
-
Down Syndrome / physiopathology
-
Female
-
Genotype
-
Humans
-
Male
-
Middle Aged
-
Peptide Fragments / analysis
-
Peptide Fragments / blood
-
Sex Factors
Substances
-
Amyloid beta-Peptides
-
Apolipoproteins E
-
Biomarkers
-
Peptide Fragments
-
amyloid beta-protein (1-40)
-
amyloid beta-protein (1-42)